AFT Pharmaceuticals Ltd. (AU:AFP)
ASX:AFP
Australian Market
Holding AU:AFP?
Track your performance easily

AFT Pharmaceuticals Ltd. (AFP) Income Statement

5 Followers

AFT Pharmaceuticals Ltd. Income Statement

Last quarter (Q4 2022), AFT Pharmaceuticals Ltd.'s total revenue was $―, a decrease of ― from previous quarter. In Q4, AFT Pharmaceuticals Ltd.'s net income was $―. See AFT Pharmaceuticals Ltd.’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Mar 22Mar 21Mar 20Mar 19
Total Revenue
-$ 129.83M$ 113.11M$ 105.60M$ 85.13M
Cost of Revenue
-$ 68.54M$ 64.36M$ 57.33M$ 44.40M
Gross Profit
-$ 61.30M$ 48.74M$ 48.27M$ 40.73M
Operating Expense
-$ 42.66M$ 39.76M$ 38.08M$ 36.33M
Operating Income
-$ 18.64M$ 8.98M$ 10.19M$ 4.40M
Net Non Operating Interest Income Expense
-$ -2.43M$ -3.44M$ -8.33M$ -8.38M
Other Income Expense
-$ 1.43M$ 1.24M$ 10.24M$ 1.72M
Pretax Income
-$ 18.68M$ 7.89M$ 12.88M$ -2.26M
Tax Provision
-$ -1.16M$ 105.00K$ 185.00K$ 168.00K
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
-$ 19.85M$ 7.78M$ 12.69M$ -2.43M
Basic EPS
-$ 0.19$ 0.08$ 0.13$ -0.02
Diluted EPS
-$ 0.19$ 0.08$ 0.13$ -0.02
Basic Average Shares
-$ 104.68M$ 103.30M$ 97.31M$ 97.31M
Diluted Average Shares
-$ 104.68M$ 103.30M$ 97.31M$ 97.31M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
-----
Net Income From Continuing And Discontinued Operation
-$ 19.85M$ 7.78M$ 12.69M$ -2.43M
Normalized Income
-$ 19.85M$ 7.78M$ 12.69M$ -2.43M
Interest Expense
-$ 2.44M$ 3.44M$ 8.05M$ 8.42M
EBIT
-$ 21.12M$ 11.33M$ 20.93M$ 6.16M
EBITDA
-$ 22.16M$ 12.43M$ 21.71M$ 6.16M
Currency in NZD

AFT Pharmaceuticals Ltd. Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis